Status:
COMPLETED
OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab
Lead Sponsor:
McMaster University
Collaborating Sponsors:
Hamilton Health Sciences Corporation
St. Joseph's Healthcare Hamilton
Conditions:
Wet Macular Degeneration
Eligibility:
All Genders
18-100 years
Phase:
PHASE2
Brief Summary
In the Western World, Age Related Macular Degeneration (ARMD) is a leading cause of blindness. This disease was once thought to be a natural part of aging, but recent research has introduced effective...
Detailed Description
Age Related Macular Degeneration (ARMD or AMD) is the leading cause of blindness in North America. There are two types of ARMD: dry and wet. Both forms of ARMD cause a progressive loss of central visi...
Eligibility Criteria
Inclusion
- Patients with wet age-related macular degeneration (ARMD) with evidence of sub-foveal choroidal neo-vascularization (CNV)
- Patients greater than the age 18 years old (male or female)
- Visual acuity must be between 20/40 and 20/320 in the study eye.
Exclusion
- Patients with CNV from causes other than ARMD
- Patients having intra-ocular surgery within past 3 months on study eye
- Patients with medically uncontrolled glaucoma
- Patients with prior vitreous/retinal surgery
- Patients with a history of past CNV treatment in study eye
- Patients with other ocular conditions causing vision loss that could confound the analysis of ARMD
- Individuals with a disability preventing accurate vision testing
Key Trial Info
Start Date :
March 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2015
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT01243086
Start Date
March 1 2011
End Date
May 1 2015
Last Update
April 6 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St. Joseph's Healthcare Hamilton Regional Eye Centre
Hamilton, Ontario, Canada, L8G 5E4